Read Gene

Read Gene Graham Number

The Graham Number of Read Gene (RDG.WA) as of Oct 22, 2026 is 0.22 PLN. In the previous year, Graham Number was 13.73 PLN — a change of -98.39% (lower).

Graham Number

0.22PLN

YoY

-98.39%

Last updated:

Graham Number of Read Gene is 2025 0.22 PLN. Graham Number of Read Gene was 2024 13.73 PLN. It decreases by -98.39% lower compared to the previous year.

The Read Gene Graham Number history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Graham Number
Date
Graham Number
Jan 1, 2018
0.68 PLN
Jan 1, 2020
0.39 PLN
Jan 1, 2021
5.76 PLN
Jan 1, 2022
13.73 PLN
Jan 1, 2025
0.22 PLN
The Read Gene Graham Number history
YEARGraham NumberYoY
0.22PLN-98.39%
13.73PLN+138.21%
5.76PLN+1,379.10%
0.39PLN-42.78%
0.68PLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Read Gene Stock analysis

What does Read Gene do? Read Gene SA generates revenue through medical research and testing services, focusing on malignant tumor detection, prevention, and treatment. The company offers breast cancer, colon cancer, and prostate cancer tests, along with medical consultancy, DNA tests, and supplements. Its subsidiary Dieta Antyrakowa Read-Gene Sp. z o.o. supports these services, while major shareholder GEN-PAT-MED Sp. z o.o. provides strategic backing. Clients include patients seeking cancer diagnostics and preventive care, as well as healthcare providers integrating these tests into treatment protocols. The firm's chemoprevention, clinical trials, and genetic testing specialties drive product sales to hospitals, clinics, and individual consumers. Breast cancer, colon cancer, and prostate cancer tests are key revenue streams, complemented by DNA tests and supplements. Medical consultancy services cater to institutions requiring expert guidance on cancer-related health strategies. Read Gene SA's product portfolio is structured around three core fields: chemoprevention, clinical trials, and genetic testing. The company monetizes genetic testing services, particularly for breast, colon, and prostate cancers, alongside DNA tests and supplements. Healthcare institutions and private clients form the primary customer segments, with Dieta Antyrakowa Read-Gene Sp. z o.o. serving as the operational arm for these offerings. Read Gene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Read Gene stock

Graham Number of Read Gene is 0.22 PLN in 2025.

On Eulerpool you can find the complete historical development of Graham Number Read Gene since 2006 – with annual values, charts, and detailed analysis.

The Graham Number estimates the maximum fair price for a stock based on EPS and book value per share, following Benjamin Graham's value investing principles.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Read Gene

All Key Metrics — Read Gene